Thaminda Ramanayake

CBO at CureVac

Speaker

Thaminda Ramanayake, MBA, is the Chief Business Officer of CureVac, NV, (NASDAQ: CVAC), a pioneer in mRNA medicines. He has spent over a decade working to bring value to patients globally and has a strong track record in business development & licensing, company creation, M&A, joint ventures, corporate strategy and cross-border transactions. Previously, he served as the Chief Business Officer of Affini-T Therapeutics, a privately held T cell therapy company. Prior to that, Thaminda was the Vice President, Global Head of Business Development, Oncology at Sanofi, shaping the company’s oncology business strategy and leading various collaborations from clinical trial supply agreements to various complex multi-billion dollar deals. Prior to Sanofi, Thaminda served as Senior Director, Business Development & Strategy at BioMarin Pharmaceutical, where he led the negotiation and execution of various licensing deals, spin-outs, and financing initiatives. Early in his career, Thaminda held transaction advisory and consulting roles at Grant Thornton, Ernst & Young and Empire Valuation Consultants.

He earned his B.A. in molecular, cellular and systems biology from Berea College and his M.S. in immunology from the University of Rochester School of Medicine and Dentistry. He received his MBA in finance from the University of Rochester Simon Business School.